MKI67 and neoplasm: In vivo, a subcutaneous U2OS xenograft model showed significantly reduced tumour volume and final tumour weight following combination treatment, accompanied by decreased Ki-67 expression and no observable systemic toxicity, confirming both efficacy and safety.